|

Abemaciclib Clinical Trials

58 actively recruiting trials across 30 locations

Also known as: Abemaciclib Oral, C27H32F2N8, CDK4/6 Inhibitor Therapy., LY 2835219, LY-2835219, LY2835219, RO7071651, Ramiven, Venizio, Verzenia, Verzenio, Verzenios, Verzenio™

Other8 trials

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Phase 2
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Phase 2
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Phase 2
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Phase 2
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Birmingham, Alabama5 trials

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Childrens Hospital of Alabama

Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

University of Alabama at Birmingham

Phase 2
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

The Kirklin Clinic of UAB Hospital

Phase 3
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California5 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

City of Hope

Phase 1/2
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

City of Hope Medical Center

Phase 2

Boston, Massachusetts5 trials

ALPINE: Maintenance Letrozole/Abemaciclib

Beth Israel Deaconess Medical Center

Phase 2
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Dana Farber Cancer Institute

Phase 1/2
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Massachusetts General Hospital Cancer Center

Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Dana Farber Cancer Institute

Phase 2
VS-6766+Abema+Fulv in Met HR+/HER- BC

Massachusetts General Hospital Cancer Center

Phase 1/2

Los Angeles, California3 trials

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

University of Southern California

Phase 1/2
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Keck Medicine of USC Koreatown

Phase 1

Dothan, Alabama2 trials

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Dothan Hematology and Oncology

Phase 1/2

Phoenix, Arizona2 trials

Abemaciclib in Newly Diagnosed Meningioma Patients

St. Joseph's Hospital and Medical Center

Phase 2
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Mayo Clinic Hospital in Arizona

Phase 1

Tampa, Florida2 trials

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Moffitt Cancer Center

Phase 2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Moffitt Cancer Center

Phase 1/2

Bethesda, Maryland2 trials

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

National Institutes of Health Clinical Center

Phase 1/2
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

National Institutes of Health Clinical Center

Phase 1/2

St Louis, Missouri2 trials

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Research Site

Phase 1/2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Memorial Sloan Kettering at Basking Ridge (All protocol activities)

Phase 1
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Memorial Sloan Kettering Basking Ridge

Phase 2

Daphne, Alabama1 trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Southern Cancer Center

Phase 3

Anchorage, Alaska1 trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Scottsdale, Arizona1 trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Mayo Clinic Scottsdale

Phase 1/2

Tucson, Arizona1 trial

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Research Site

Phase 3

Fullerton, California1 trial

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Providence Medical Foundation

Phase 1/2

Irvine, California1 trial

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1

San Francisco, California1 trial

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2

New Haven, Connecticut1 trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

Yale Cancer Center

Phase 1/2

Washington D.C., District of Columbia1 trial

ETHAN - ET for Male BC

Georgetown University Medical Center

Phase 2

Jacksonville, Florida1 trial

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Mayo Clinic

Phase 2

Lake Mary, Florida1 trial

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Florida Cancer Specialists

Phase 1/2

Chicago, Illinois1 trial

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

University of Illinois

Phase 4

Baltimore, Maryland1 trial

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Johns Hopkins University (Data Collection Only)

Phase 1/2

Lebanon, New Hampshire1 trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Dartmouth Hitchcock Medical Center

Phase 2

Belleville, New Jersey1 trial

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

RWJBarnabas Health Clara Maas Medical Center

Phase 1

New York, New York1 trial

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Mount Sinai Beth Israel

Phase 1/2

Philadelphia, Pennsylvania1 trial

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

Abramson Cancer Center of the University of Pennsylvania

Phase 2

Dallas, Texas1 trial

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Parkland Hospital

Phase 2

Houston, Texas1 trial

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

M D Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.